New Diabetes Pill Delivers 89% Success Rate in Trial

Nearly 90% of people taking a new diabetes pill reached healthy blood sugar levels in a groundbreaking trial that could transform treatment for millions living with type 2 diabetes.

The experimental medication, called elecoglipron, delivered powerful results in a 26-week study involving 406 adults across nine countries. Researchers from Mass General Brigham presented the findings at the American Diabetes Association's Scientific Sessions, with results published simultaneously in The Lancet.

Up to 89.6% of participants taking the pill achieved the standard blood sugar target, compared to just 24.9% in the placebo group. That's a success rate nearly four times higher than what patients experienced without the medication.

The pill also produced meaningful weight loss, with up to 72.3% of users losing at least 5% of their body weight. Only 20.2% of people taking the placebo achieved similar results.

Dr. Vanita Aroda, who leads Diabetes Clinical Research at Mass General Brigham, says the results highlight growing potential for oral medications that could be easier to use than current options. Most GLP-1 diabetes treatments require daily or weekly injections, which can be a barrier for many patients.

While one oral GLP-1 medication already exists, it comes with strict rules. Patients must take it first thing in the morning on an empty stomach and avoid food and water for 30 minutes afterward.

The new pill was designed specifically for type 2 diabetes treatment and showed a safety profile consistent with other GLP-1 therapies at this stage of development. Researchers evaluated different starting doses and approaches to find the most effective treatment plans.

Why This Inspires

This research represents more than just another medication option. It could remove significant barriers that prevent people from accessing effective diabetes care. The convenience of a simple pill, combined with such strong results, means more people might actually stick with their treatment long term.

The study also demonstrates how carefully designed clinical trials continue advancing diabetes care, turning scientific discoveries into real solutions that improve daily life for millions.

Better diabetes management isn't just about numbers on a chart. It means fewer complications, better quality of life, and more energy to spend with loved ones and doing what matters most.